KERN, BRDG and CAC have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2023.
KERN, ILLM and ATIP have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2023.
Tough competition and consistent net loss continue to pose threats to Cardiovascular Systems (CSII).
Quest Diagnostics (DGX) is building strong platforms to focus on high-growth areas like molecular genomics and oncology.
Investors are optimistic about Boston Scientific (BSX), led by impressive value-added acquisitions.
Bruker (BRKR) extends support to the expansion efforts of the UK Science community by providing 1.2 GHz Avance NMR spectrometers.
Tandem Diabetes (TNDM) demonstrated positive results from the clinical trial of advancing its Control-IQ technology to younger age group patients.
Medtronic's (MDT) Affera Mapping and Ablation System is intended to treat atrial arrhythmias.
Abbott (ABT) currently forecasts total organic sales growth, excluding the impact of COVID testing-related sales, to be in the high-single digits in 2023.
According to NuVasive (NUVA), the combined company is set to have an advanced commercial scale and portfolio of clinically proven solutions.